| Literature DB >> 28717082 |
Hirotsugu Ariizumi1, Yosuke Sasaki2, Hiroshi Harada1, Yui Uto1, Remi Azuma1, Tomohide Isobe3, Koji Kishimoto3, Eisuke Shiozawa2, Masafumi Takimoto2, Nobuyuki Ohike3, Hiraku Mori1.
Abstract
The pathogenesis of cerebral/renal salt-wasting syndrome remains unknown. We herein present a case of salt-wasting syndrome with a natural killer-cell neoplasm without cerebral invasion. A 78-year-old man with hemophagocytic syndrome received two cycles of chemotherapy that did not induce tumor lysis syndrome, but repeatedly caused polyuria and natriuresis. The expression of tumor necrosis factor-α in the neoplasm led us to hypothesize that an oncolysis-induced cytokine storm may have caused renal tubular damage and salt wasting. Our theory may explain the pathogenic mechanism of cerebral/renal salt-wasting syndrome associated with other entities, including cerebral disorders, owing to the elevation of cytokine levels after subarachnoid hemorrhage.Entities:
Keywords: cerebral salt wasting syndrome; pathogenesis; pathophysiology; renal salt wasting syndrome; tumor necrosis factor-alpha
Mesh:
Substances:
Year: 2017 PMID: 28717082 PMCID: PMC5548679 DOI: 10.2169/internalmedicine.56.8125
Source DB: PubMed Journal: Intern Med ISSN: 0918-2918 Impact factor: 1.271
Figure 1.The pathology of the NK-cell neoplasm with lymphoma-associated hemophagocytic syndrome from a resected lymph node. There are an increased number of atypical lymphoid cells with hemophagocytosis (arrow) on Hematoxylin and Eosin (HE) staining (a, ×40 of objective lens magnification). Immunohistochemical assay showed the immunophenotypes of the neoplasm: CD3+(b, ×40), CD4+, CD8−, CD20−, CD30+, and CD56+. The Ki-67 index was >90% (c, ×40). The neoplastic cells contained granzyme B (d, ×40). Immunohistochemical analysis of the stored biopsy samples also revealed expression of TNF-α+ (e, ×40) and TGF-β1+ (f, ×40), using TNFα (52B83) antibody (1:100 dilution; sc-52746; Santa Cruz Biotechnology, Dallas, USA), and TGFβ1 (V) antibody (1:200 dilution; sc-146; Santa Cruz Biotechnology), respectively (13, 14). Hybrid fluorescence imaging of immunostaining and Epstein-Barr virus-encoded small RNA (EBER)in situ hybridization precisely confirmed the immunophenotypes: green indicates EBER; red indicates CD56 (g, ×60) and TNF-α (1: 100 dilution; sc-52746; h, ×60) in each image; blue indicates DAPI-stained DNA. The component fluorescence images were taken with a fluorescence microscope BZ-8100 (Keyence, Osaka, Japan) by the second author.
Figure 2.Clinical course and laboratory findings in this case. The results of the lymph node biopsy (*) after methylprednisolone pulse therapy supported the use of chemotherapy for steroid-resistant high fever. The CHOP-like chemotherapies (down arrows) on hospital days 17 and 37 (vertical dashed lines) induced persistent polyuria and natriuresis after transient lactate dehydrogenase (LDH) surges in conjunction with the elevation of serum ferritin levels, with administration of corticosteroids with physiological mineralocorticoid potency. Negative fluid balance, negative sodium (Na) balance and body weight loss indicated volume depletion and salt wasting along with the polyuria. The low serum uric acid (UA) levels persisted even after recovery from the hyponatremia. Potassium (K) levels were managed with intravenous supplementation. The decreasing of granzyme B level on hospital days 28 reflected tumor burden; the simultaneous (as shown by vertical dotted lines) increase in CD365 levels indicated renal tubular damage. Fractional excretion of sodium (FENa) exceeded adequate FENa during polyuria, except during fever after the transient hypovolemic shock (§). This excess also suggested tubular dysfunction rather than tubular adaptation (16). Urine volume and urinary sodium excretion were independent of creatinine clearance (Ccr) levels, apart from sole spike of Ccr on hospital day 22. The administered steroid doses are shown to be equivalent to glucocorticoid and mineralocorticoid potencies of prednisolone by the following conversion coefficients: hydrocortisone, ×0.25 in glucocorticoid potency (dashed line), ×1.25 in mineralocorticoid potency (solid line); prednisolone, ×1.0, ×1.0; methylprednisolone, ×1.25, ×0.625; betamethasone, ×6.25, ×0.0 (17-19). Fluid intake includes oral fluids (negligible since hospital day 34), infused solutions, and transfusions. Sodium intake includes dietary salt (negligible since hospital day 24) and infused sodium. These were calculated from his dietary intake and infused dose, respectively, on the observation chart recorded during nursing. The urinary sodium excretion [mEq/day] was estimated by urine volume [mL/day] × urinary sodium concentration [mEq/mL] (sampled from pooled urine in a collection bag, but not 24-hour pooled urine). The Ccr [mL/min per body surface area 1.73 m2] was estimated by the following formula: urine creatinine concentration [mg/dL] (same samples as for urinary sodium excretion) × urine volume [mL/min] ×1.73/(serum creatinine concentration [mg/dL] × a constant value of patient’s body surface area [m2]). The FENa [%] was calculated by the following formula: 100× urinary sodium concentration [mEq/L] × serum creatinine concentration [mg/dL]/(serum sodium concentration [mEq/L] × urinary creatinine concentration [mg/dL]). The adequate FENa [%] was calculated by the following formula (16): sodium intake [mEq/day] / (0.0144× Ccr [mL/min] × serum sodium concentration [mEq/L]). The dagger (†) represents the patient’s death. The black triangle (▲) represents amikacin (AMK) and the open inverted triangle (▽) represents vancomycin (VCM). This figure was drawn using the ggplot2 software package, version 2.0.0 in R, version 3.2.2.